Company Overview

PolyNovo (ASX: PNV) is an Australian-based medical technology company headquartered in Port Melbourne, Victoria, specialising in advanced wound care and dermal regeneration. The company designs, develops, manufactures, and commercialises innovative medical devices using its patented NovoSorb biodegradable polymer platform. Its flagship product, NovoSorb BTM, is widely used for the treatment of burns, surgical wounds, trauma, and other complex tissue-loss conditions, with the majority of revenue generated in the United States. Originally listed on the ASX on 26 November 1998 as Calzada Limited, the company rebranded to PolyNovo in November 2014. You can read our initiation coverage of PolyNovo (ASX: PNV) here.

Core Technology: NovoSorb

PolyNovo's entire product ecosystem is built on NovoSorb, a family of proprietary, medical-grade bioabsorbable polymers that can be expressed in a variety of physical formats, including film, fibre, foam, and coatings. These polymers offer key properties such as biocompatibility, design flexibility, and a programmable bio-resorption profile — they safely biodegrade in the body into harmless byproducts, which are fully absorbed within approximately 18 months.

Business Segments and Field of Activity

The company’s key products include:

1- NovoSorb BTM is a dermal scaffold for wound closure and skin regeneration in burns, trauma, and surgery, and it serves as the company’s core commercial product.

2- NovoSorb MTX is a next‑generation advanced wound care product launched in the U.S. in Q4 2024; it has shown rapid growth, rising 195.2% to A$6.2 million in H1 FY26.

3- Breast Sling is a bioabsorbable support device currently in development.

4- Hernia Repair is a mesh device using NovoSorb technology that is also in the pipeline or development stage.

5- Orthopaedic Applications focus on bone and tissue repair and are in the pipeline or at the development stage.

Strategic Initiatives

PolyNovo's strategic priorities are centred on accelerating commercial growth and expanding its clinical footprint:

· U.S. Market Penetration: The U.S. remains the primary growth driver. The company achieved 25.3% revenue growth in H1 FY26 in this market, supported by a dedicated direct sales force.

· BARDA Partnership: PolyNovo completed a U.S. Pivotal Trial for full-thickness burns with BARDA (Biomedical Advanced Research and Development Authority), a major U.S. government health agency, supporting regulatory and reimbursement credibility.

· Innovation Pipeline Acceleration: The company is advancing its development program into Breast Sling, Hernia, and Orthopaedic applications to diversify revenue beyond wound care.

· Reimbursement Expansion: Management has highlighted "increasingly favourable reimbursement dynamics" as a key growth lever, particularly in the U.S.

· Global Market Expansion: Ongoing growth across Europe, Asia, and the Middle East through the "Rest of World" segment.

A closer look at the key reasons behind the latest price movement in PolyNovo (ASX: PNV)

PolyNovo’s share price has moved through a period of initial pressure, followed by a recovery as the market reassessed both risk and growth prospects. The next section explains the specific factors that drove the March weakness and the later improvement in sentiment, including leadership changes, revenue momentum, and expectations for stronger operating performance.

· March weakness was triggered by leadership uncertainty. PolyNovo’s share price fell after the CEO’s exit, and the market also reacted to governance concerns and the risk of execution disruption.

· Growth then reasserted itself through stronger revenue momentum. Despite the March shock, PolyNovo continued to post solid sales growth, which helped investors look past the headline risk and focus on the underlying commercial ramp.

· Improving H2 expectations supported sentiment. Market commentary pointed to the possibility of better profit and cash flow in the second half as manufacturing normalised and capital spending eased.

· The stock also benefited from a low starting point. After the March sell-off, even modestly positive trading updates or signals of an improving outlook were enough to trigger a rebound from depressed levels.

Important Disclaimer: You’re reading a free article that offers general opinions and insights. For exclusive, in-depth research, timely high-conviction investment ideas, and actionable trade signals designed to help you stay ahead, join Proactive Equities today by opening a Free Trial Account now! (No Credit Card Required)

Technical Analysis of PolyNovo (ASX: PNV)

Source: TradingView

Market movement remains consistent with our previous analysis. Here’s our updated view.

Price action

PolyNovo has exhibited a well-defined downtrend since its September 2025 peak near 1.70–1.75. Price accelerated lower through late 2025 and early 2026. A decisive breakout above the descending trendline occurred in mid-April 2026, marked with a "Breakout" label, signalling a potential trend reversal. The subsequent price surge in May pushed the stock above $1.20, though recent candles show a slight pullback/consolidation from that high. This sequence forms a classic breakout-and-retest pattern.

Key Price Levels

Support: The breakout-retest zone around 1.05–1.08 is acting as immediate support; a daily close below this would weaken the bullish structure.

TP1 / TP2 targets: As long as the price remains above the support level, a retracement towards TP1 (around 1.30) is the first logical resistance, and TP2 (around 1.45-1.50) is also possible if trading volume increases and more bullish catalysts occur.

Stop-loss: The red band around 0.85 is the key invalidation area; losing this suggests the breakout failed, and the trend could revert down.

Volume

Volume during the September–December downtrend was generally subdued and declining. A notable volume expansion occurred during the April breakout, confirming institutional participation in the reversal. The current volume reading of 2.86 million suggests above-average participation, though the pullback from the May peak has moderated. A high-volume breakout followed by a pullback on lighter volume is a bullish signal.

RSI~60

RSI is sitting around 59.58, which is above the neutral 50 line but still below overbought territory. That usually indicates improving momentum without yet showing exhaustion. The recent jump in RSI supports the bullish breakout attempt, but it would be stronger if RSI holds above 50 on any pullback.

FAQs about PolyNovo (ASX: PNV)

1- Why is PolyNovo important in wound care?

PolyNovo is important because its biodegradable polymer technology offers an advanced option for wound reconstruction and healing. Its products are used in difficult clinical cases such as burns and major tissue loss, where traditional treatment options can be limited.

2- Who are PolyNovo’s customers?

PolyNovo’s customers are typically hospitals, surgeons, burn specialists, and healthcare providers who treat complex wounds and reconstructive cases. Its products are used in clinical environments where advanced wound management is needed.

3- Does PolyNovo have a competitive moat?

PolyNovo’s competitive advantage stems from its patented NovoSorb platform and its clinical focus on advanced wound care. However, the medical device market is competitive, so continued product adoption, evidence generation, and international expansion are important to defend its position.